Floatz Rating
B57/100
Confidence
Indicative
Sponsor
Mansoura University
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
42Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06186700CT.gov Effect of Pentoxifylline on Preventing Chemotherapy-induced Toxicities in Patients With Breast Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Chemotherapy-Induced Neuropathy
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Pentoxifylline (this asset) | Mansoura University | P2 | B · 57 |
| Pregabalin | University of Rochester | P4 | BB |
| Omeprazole | Aya Mohamed Sadek Elsaid | P3 | BB |
| Lidocaine | Hospital Ambroise Paré Paris | P2 | BB |
| Mecobalamin | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | P2/3 | B |
| Pyridoxol | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | P2/3 | B |
| Danggui-Sini Granules | Nanjing NingQi Medicine Science and Technology Co., Ltd. | P3 | B |
| Sodium Selenite Pentahydrate | Seoul National University Hospital | P3 | B |
| Huangqi-Guizhi-Wuwu Granules | Nanjing NingQi Medicine Science and Technology Co., Ltd. | P3 | B |
+36 more in the Chemotherapy-Induced Neuropathy cohort
Other indications for Pentoxifylline
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Metabolic Dysfunction-Associated Steatohepatitis | — | P4 | BBB · 76 |
| Type 2 Diabetes Mellitus | — | P4 | BB · 68 |
| Peripheral Neuropathy | — | P2/3 | BB · 66 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Pentoxifylline in Chemotherapy-Induced Neuropathy. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/pentoxifylline-chemotherapy-induced-neuropathy
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →